DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

FDA gives green light to new United Imaging PET/MR scanner The uPMR 790 HD TOF performs total-body scans within 20 minutes

FDA reminder for properly eluting rubidium 82 generators prompted by 'recent incidents' Using incorrect solutions puts patients at risk

Generating higher quality PET images 100x faster at MSK 'No one has done PET imaging in this way before'

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

Rhodotron TT300 HE electron
beam accelerators

NorthStar buys IBA electron accelerators for Mo-99 production

by John R. Fischer , Staff Reporter
NorthStar Medical Radioisotopes has put forth downpayments for two Rhodotron TT300 HE electron beam accelerators produced by Ion Beam Applications (IBA).

The purchase and installation of the systems will enable the Wisconsin-based nuclear medicine enterprise to increase its production capacity and efficiencies, and create manufacturing redundancies that secure its supply of non-uranium-based, molybdenum-99 (Mo-99) radioisotopes for U.S. customers and patients.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED

“The electron accelerators offer advantages in being one of the most effective methods of producing Mo-99, in addition to providing customized flexibility to accommodate customer needs, and production redundancies to minimize risks to customer supply,” Stephen Merrick, president and chief executive officer of NorthStar, told HCB News. “Adding accelerator production is one aspect of NorthStar's carefully staged approach to providing and expanding capacity for Mo-99 production in the United States.”

The machines will assist NorthStar in combating shortages of Mo-99, which will then be converted by the company’s RadioGenix system into technetium-99m (Tc-99m) for use in diagnostic imaging exams, such as for heart disease, cancer, infection, and inflammation, among other conditions. They also will be used in the production of new radiopharmaceuticals for diagnosis and treatment.

Each costing more than $6.7 million, the two will be installed in a 10,000-sq. ft. facility expansion, the groundbreaking of which is planned to take place in the next year in Beloit, Wisconsin. Construction will run parallel to the manufacturing of the accelerators and other equipment provided by IBA.

The installations build upon a number of milestones achieved by NorthStar over the past year, including the FDA clearance and first order of its RadioGenex System.

“Upon installation, which is expected in 2020, the facility and equipment will require appropriate validations, licensing and FDA approval(s) prior to use,” said Merrick. “Our ramp-up production capacity plans are underway to consistently meet more than 2/3 of market demand, and surge capacity would eventually provide the potential to meet total market demand.”

The need for domestic supplies of Mo-99 in the U.S. is a topic of great concern in the nuclear medicine world and one that recently pushed the Department of Energy to open up negotiations for potential new cooperative agreement awards with NorthStar and three other companies, to facilitate production of non-uranium-based Mo-99. NorthStar is the first domestic source of Mo-99 in nearly 30 years for the U.S.

The company plans to acquire and install six more Rhodotron systems from IBA in the coming years.

Operations at the new facility are expected to begin in 2021.

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2019, Inc.